Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
Overall survival data further support sacituzumab govitecan in HR+/HER2– metastatic breast cancer
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
Managing ovarian cancer in the PARP inhibitor era
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Combining PARP1 inhibition with an ATR inhibitor does not improve outcomes in pre-treated metastatic TNBC
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib
Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations
Poziotinib does not meet the expectations to target insertion mutations in HER2 exon 20 in NSCLC
The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor